![Nicoletta Loggia](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 17 770 $ al 31/05/2026
Nicoletta Loggia is currently an Independent Director at Candel Therapeutics, Inc. since 2023 and Chief Technical Officer at Orchard Therapeutics Plc since 2021.
Formerly, Dr. Loggia was Head of Cell & Gene Therapies at Novartis AG from 2015 to 2021.
Education includes graduate and doctorate degrees from the University of Pavia.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 30/06/2026 | 2.141 ( 0 % ) | 17 770 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Director Técnico/Científico/I+D | 09/09/2021 |
| CANDEL THERAPEUTICS, INC. | Director/Miembro de la Junta | 07/06/2023 |
| Empresas | Cargo | Fin |
|---|---|---|
| NOVARTIS AG | Corporate Officer/Principal | 01/08/2021 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
University of Pavia
 University of Pavia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Candel Therapeutics, Inc.
 Candel Therapeutics, Inc. BiotechnologyHealth Technology Develops and distributes immunotherapies for the treatment of cancer | Health Technology |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc BiotechnologyHealth Technology Engages in research and advancements of gene therapy to develop potential cures for genetic & other severe diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
